Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
1. A pharmaceutical composition comprising a compound of Formula II,
or salt thereof, wherein:
m is 1 or 2;
n is 2;
E is NH, S, or O;
W is CX 6 or N;
X 1 , X 3 , and X 4 are hydrogen;
X 2 is hydrogen or halogen;
X 5 is methyl or trifluoromethyl;
X 6 is hydrogen;
Y 2 and Y 4 are each, the same or different, hydrogen, 2-hydroxyethoxy, alkyl, halogen, or alkoxy; and
Y 30 hydroxy.
2. The pharmaceutical composition of claim 1 wherein the compound is 3-(4-(2-hydroxyethoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl) acrylamide or salt thereof.
3. The pharmaceutical composition of claim 1 wherein the compound is 3-(3,4-bis(2-hydroxyethoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide or salt thereof.
4. A pharmaceutical composition comprising a compound of Formula III,
or salt thereof, wherein:
m is 1 or 2;
n is 2;
p is 1 or 2;
E is NH, S, or O;
W is CX 6 or N;
X 1 , X 3 , and X 4 are hydrogen;
X 2 is hydrogen or halogen;
X 5 is methyl or trifluoromethyl;
X 6 is hydrogen;
Y 1 , Y 2 , and Y 5 are hydrogen;
Y 30 is hydroxy; and
Y 40 is hydroxy.